Dr Reddys Laboratories (RDY) Gross Profit (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported Gross Profit for 15 consecutive years, with $486.0 million the latest figure, recorded in Q2 2023.

• Quarterly Gross Profit changed N/A year-over-year to $486.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $488001.4 billion (changed N/A YoY) and the FY2026 annual result came in at $1.9 billion, down 15.29% from the prior year.
• Gross Profit rose to $486.0 million in Q2 2023 per RDY's latest filing, from $476.0 million in the prior quarter.
• Over the last five years, Gross Profit for RDY reached as high as $488000.0 billion in Q3 2022 and fell as low as $281.0 million in Q1 2019.
• A 5-year average of $40667.0 billion and a median of $375.0 million in 2019 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2019 — Gross Profit jumped 34.38% — and 2020, when it dropped 6.46%.
• Year by year, Gross Profit stood at $332.0 million in 2019, then advanced by 9.34% to $363.0 million in 2020, then climbed by 14.33% to $415.0 million in 2021, then gained by 5.78% to $439.0 million in 2022, then rose by 10.71% to $486.0 million in 2023.
• According to Business Quant data, Gross Profit over the past three periods registered $486.0 million, $476.0 million, and $439.0 million for Q2 2023, Q1 2023, and Q4 2022 respectively.